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Abstract
The re-emergence of tuberculosis (TB) as a global public health threat highlights the necessity of rapid, simple and
inexpensive point-of-care detection of the disease. Early diagnosis of TB is vital not only for preventing the spread of the
disease but also for timely initiation of treatment. The later in turn will reduce the possible emergence of multi-drug
resistant strains of Mycobacterium tuberculosis. Lipoarabinomannan (LAM) is an important non-protein antigen of the
bacterial cell wall, which is found to be present in different body fluids of infected patients including blood, urine and
sputum. We have developed a bispecific monoclonal antibody with predetermined specificities towards the LAM antigen
and a reporter molecule horseradish peroxidase (HRPO). The developed antibody was subsequently used to design a simple
low cost immunoswab based assay to detect LAM antigen. The limit of detection for spiked synthetic LAM was found to be
5.0 ng/ml (bovine urine), 0.5 ng/ml (rabbit serum) and 0.005 ng/ml (saline) and that for bacterial LAM from M. tuberculosis
H37Rv was found to be 0.5 ng/ml (rabbit serum). The assay was evaluated with 21 stored clinical serum samples (14 were
positive and 7 were negative in terms of anti-LAM titer). In addition, all 14 positive samples were culture positive. The assay
showed 100% specificity and 64% sensitivity (95% confidence interval). In addition to good specificity, the end point could
be read visually within two hours of sample collection. The reported assay might be used as a rapid tool for detecting TB in
resource constrained laboratory settings.
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Introduction
In 2009, the World Health Organisation (WHO) reported 9.4
million cases of tuberculosis (TB) and 1.7 million deaths worldwide
[1]. In spite of the best efforts from the researchers round the
globe, TB is the leading cause of death by a single, treatable
infectious disease. In the last few decades, the situation of TB has
worsened due to co-infection with the Human Immune Deficiency
(HIV) virus and the emergence of multi-drug resistant (MDR) and
extremely drug resistant (XDR) strains of M. tuberculosis. In one
study, it was estimated that 70% of the AIDS (acquired
immunodeficiency syndrome) patients are infected with at least
one of the opportunistic mycobacteria pathogens [2]. One of the
major reasons for the increased incidence of TB is the lack of a
rapid, sensitive, specific, and inexpensive point-of-care (POC)
diagnosis for TB. It should be noted that development of new
diagnostics for TB has been emphasized as one of the six strategies
in the WHO recommendations to combat the spread of the disease
[3].
Currently, the diagnosis of TB mainly relies on sputum smear
microscopy (SSM), which often gives false negative results. In
addition, clinical symptoms and results of chest x-rays are non-
specific, making them less reliable. In recent times, more advanced
molecular assays like the interferon gamma release assay (IGRA)
and the nucleic acid amplification (NAA) assay have been
developed but their utility as a POC assay is questionable [4–6].
It should be noted, however, that a recent study concluded that in
resource-limited environments, a combination of sputum smear
microscopy and Xpert-MTB/RIF (an NAA assay) led to both
higher accuracy and lower cost of the diagnosis, compared to
when the use of a single one of these assays [7]. Nevertheless, these
assays can be difficult to perform in resource-constrained countries
due to their high cost and technical sophistication. The culture
method still remains the gold standard for detection of TB.
However, it takes 2–6 weeks to obtain the results, which limits the
ability of the health care system to contain the infection and
provide suitable medical intervention to the patient in a timely
manner. A good number of reviews are available in literature that
discusses the advantages and disadvantages of various available
detection tests for TB and criteria for an emerging detection assay
[8–11]. The impact of POC assay is even greater in resource-
constrained settings especially as 86% of the TB cases are reported
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diagnosis of TB could facilitate proper evaluation of new anti-
tuberculosis vaccine trials [12].
Early diagnosis of TB is of paramount importance because TB
is highly contagious during the active stage of the disease. A rapid
and specific detection of the disease is therefore vital to contain the
spread of TB and at the same time will help physicians to initiate
proper and timely treatment, which in turn can reduce the chance
of bacterial evolution towards MDR and XDR strains [13].
Recent research has led to the identification of several new
antigens that could be used for the diagnosis of TB. One such
antigen is lipoarabinomannan (LAM), an important non-protein
antigen that constitutes 40% of the mycobacterial cell wall [14],
and which can modulate the immune response of the host [15–18].
Several studies have shown the presence of LAM in different body
fluids like sputum, blood and urine during TB [19–21]. In
addition, LAM is also present in pleural fluid and cerebrospinal
fluid of patients with extra pulmonary TB [22–24]. These findings
highlight the importance of this antigen as a diagnostic marker.
Detection of antigen almost certainly confirms the presence of
active disease. In contrast, detection of antibody does not always
indicate active disease [25] as the antibody response can be
detected even six months after clearance of the infection.
The objective of this study was to develop an enzyme-linked
immunosorbent assay (ELISA)-based sensitive and specific immu-
noassay for TB detection. The ELISA was transferred onto an
immunoswab platform due to its advantage of visual end point
detection, which eliminates the need of using any instrument. The
design of the immunoswab assay is based on detection of the LAM
antigen. A bispecific monoclonal antibody (bsMAb) capable of
simultaneously binding LAM and the enzyme, horseradish
peroxidase (HRPO), was developed and used. One of the major
advantages of using bsMAb is that after two stage purification, it is
already tagged with the reporter enzyme so an extra step of
enzyme addition and the subsequent washing steps can be avoided
in the assay involving bsMAb [26]. This makes the assay faster
compared those using only monoclonal antibodies (MAb). The
immunoassay was also evaluated in another format using a
chemically conjugated MAb to compare the sensitivity of the
assay.
The assay was initially designed with a synthetic epitope of
LAM [27] spiked in rabbit serum and bovine urine and later
evaluated with native LAM. The assay was also evaluated with
stored clinical serum samples collected from TB patients. The use
of bsMAb, the first of its kind to detect any TB antigen, in the
immunoswab assay provided enhanced sensitivity with a clear
background.
Materials and Methods
2.1 Materials
Cell line: YP4, the anti-HRPO rat hybridoma cell line, and the
hybridoma cell line that produces MAb CS-35, a murine anti-
LAM antibody, were used in this study. YP4 was a kind gift from
the late Dr. C. Milstein, Medical Research Council for Molecular
Biology, Cambridge, United Kingdom while the cell line
producing CS-35 was obtained from Dr. J. S. Spencer,
Departments of Microbiology, Immunology and Pathology,
Colorado State University, USA. CS-35 is a well-characterised
MAb that specifically binds to a motif at the nonreducing terminus
of mycobacterial LAM [28–29].
Other materials and reagents: Cell culture media RPMI 1640
and Penicillin-streptomycin-glutamine (PSG) were purchased from
Gibco (New York, USA). Fetal bovine serum (FBS) was purchased
from PAA laboratories (Pasching, Austria). Goat anti-mouse IgG
conjugated to horseradish peroxidase (GAM-HRPO), bovine
serum albumin (BSA), polyethylene glycol (PEG) 1300–1600,
fluorescein isothiocyanate (FITC), tetramethylrhodamine isothio-
cyanate (TRITC), HRPO Type IV, Protein G-agarose, m-amino
phenyl boronic acid (m-APBA) agarose, and long chain sulfosucci-
nimidyl NHS biotin were purchased from Sigma Chemicals (St.
Louis, USA). Streptavidin tagged HRPO (St-HRPO) was
purchased from BD Biosciences (California, USA). Tetramethyl-
benzidine (TMB) was purchased from BioFx Laboratory (North
Carolina, USA). For Western blots, hybond-ECL nitrocellulose
membranes were procured from Amersham Biosciences, Germany
and the blot detection system was procured from GE Healthcare
(USA). Nylon fibre swabs were bought from Micro Rheologics
(Brescia, Italy). Non-sterile flat bottom NUNC maxisorp 96-well
ELISA plates were purchased from VWR (Ontario, Canada).
Fluorescence activated cell sorter, FACSAria (BD Biosciences,
USA), was accessed from the Department of Medical, Microbi-
ology and Immunology, University of Alberta. For protein
purification, we used a Biologic Duoflow system (Bio-Rad, USA)
and the ELISA absorbance was taken using Versa max microplate
reader (Molecular Devices, USA).
Rabbit serum was obtained from the Health Sciences
Laboratory Animal Services (HSLAS), University of Alberta.
Bovine urine was kindly arranged by Dr. Hoon H. Sunwoo,
Faculty of Pharmacy and Pharmaceutical Sciences, University of
Alberta.
Antigens: For the majority of this study (except the work
described in section 2.10), a chemically-synthesized hexaarabino-
furanoside epitope [27] of the LAM antigen conjugated to BSA
(BSA-Hex) was used. The loading of the hexaarabinofuranoside
on BSA was determined by MALDI-MS to be 15.2 saccharides/
BSA. Although CS-35 MAb was generated against LAM from M.
leprae [30], previous studies have demonstrated that this hexasac-
charide epitope of the LAM antigen binds strongly to it [31–32].
The BSA-Hex was used only used to design the assay. Native
LAM from M. tuberculosis H37Rv strain (used in section 2.10) was
obtained from the Biodefense and Emerging Infections Research
Resources Repository Manassas, Virginia, USA listed at http://
www.beiresources.org/TBVTRMResearchMaterials/tabid/1431/
Default.aspx.
Clinical samples: A total of 21 human serum samples (7 negative
and 14 positive) were evaluated. The positive samples were
collected from non-HIV cavitary TB patients at diagnosis prior to
initiating drug therapy who were part of a cohort of newly
diagnosed TB patients from the Tuberculosis Trials Consortium
(TBTC) Study Group 22 between 1995 and 1998 and all 14
samples were confirmed positive by culture of a respiratory
specimen [33]. The negative samples were collected from healthy
U.S. born, non-BCG vaccinated individuals from the Fort Collins,
CO, U.S.A. area in 2002. Serum samples from all sources were
anonymized and coded to protect donor identities and were
obtained with informed consent and/or with permission from the
institutional review boards of the relevant institutions involved.
The anti-LAM titer for all of these serum samples were
characterized by ELISA and Western blot in a recent study [34].
2.2 Purification and biotin labelling of CS-35 producing
MAb
The expansion, purification and characterisation of the CS-35
MAb were performed according to the published protocol [35–
36]. The biotin labelling of affinity purified CS-35 was also done as
per published protocol [35].
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formats; refer to Fig. 1) as the capture antibody. The biotin
labelled protein was employed as detection antibody in the MAb
based immunoswab assay (format 1, Fig. 1).
2.3 Development of quadroma cell line
The quadroma cell line was developed by fusing two hybridoma
cell lines, the one producing CS-35 and the other YP4. The fusion
procedure was performed following published protocols [37–39]
with slight modifications. Briefly, 2610
7 cells were isolated
separately from the two cell lines in their logarithmic growth
phase; CS-35 (re-suspended in RPMI media, pH 7.4) was labelled
with the red dye TRITC and YP4 (re-suspended in RPMI media,
pH 6.8) was labelled with the green dye FITC, and incubated for
30 minutes at 37uC and 5% CO2. The excess dye was removed by
performing repeated washes with RPMI serum free media. The
cells were then mixed well, centrifuged at 4596 g for 7 minutes
and the cell pellet was collected. The fusion of the two cell lines
was performed by drop-wise addition of 2 ml of PEG to the cell
pellet with continuous stirring for 2 minutes at 37uC. The toxic
effect of PEG was immediately minimised by diluting the mixture
with 20 ml of serum free RPMI media. This mixture was then
centrifuged at 1146 g for 5 minutes and the cell pellet was
suspended in RPMI media supplemented with 10% FBS. The
fused cells were sorted by florescence-activated cell sorting (FACS)
and the dual positive cells were seeded in a 96-well sterile tissue
culture plate at a concentration of 1 cell/well. The cells were
cultured in 20% FBS media at 37uC with 5% CO2 and their
growth was routinely monitored under the microscope. Depending
on cell growth, after approximately 9–12 days of culture, the cells
were screened for their specific activity using bridge ELISA
technique.
2.4 Bridge ELISA and sub cloning of quadroma cell line
The fused quadroma cells generally secrete three stable
antibodies, the two parent MAbs (CS-35 and YP4) and the newly
fused bsMAb [26,40]. To screen for clones that predominantly
secrete bsMAb, a bridge ELISA technique was employed [41].
The clones with maximum bsMAb secretion capacity were
identified and recloned by the standard limiting dilution method.
Briefly, the cells were plated in a tissue culture plate at a
concentration of 1 cell/well. They were then cultured as before
and positive clones were screened using bridge ELISA. The above
cloning and screening steps were repeated until a stable clone
(when cloning efficiency .80%, for details see the results) was
obtained.
2.5 Purification of bsMAb
The bsMAb producing cells were seeded in a hyper flask for
large-scale expansion, after 7–10 days the supernatant was
harvested and centrifuged at 5000 rpm for 30 minutes. The
collected supernatant was passed through a 0.22 mm filter to
remove cell debris and the clarified supernatant was further
processed to obtain pure bsMAb. A previously published two-stage
purification protocol, developed in our lab, was followed [26]. The
thus purified bsMAb was used as detection antibody in the bsMAb
based immunoswab assay (format 2, Fig. 1).
2.6 Optimization of the assay parameters:
The different parameters of the assay such as concentrations of
capture antibody (CAb), detection antibody (DAb) and St-HRPO,
were optimized separately. Optimization of the assay parameters
for format 1 (Fig. 1) is discussed below; assay parameters for format
2 were optimized in a similar manner.
Figure 1. Two formats of sandwich ELISA. Format 1: Monoclonal antibody (MAb) based, where both the capture and detection antibody are
MAb’s. Format 2: Bispecific Monoclonal antibody (bsMAb) based, where the capture antibody is a MAb but the detection antibody is a bsMAb.
doi:10.1371/journal.pone.0032340.g001
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CS-35 MAb was employed as CAb in the assay. A microtitre plate
was coated overnight at 4uC with 100 ml of different concentrations
of CS-35 MAb ranging from 0 to 16 mg/ml (0, 1, 2, 4…16) in
triplicate. The unboundbindingsites on theplate wereblocked with
250 ml of 3% dialysed BSA (DBSA) in PBS at 37uC for 3 hours.
100 ml of 5 ng/ml BSA-Hex antigen was added and incubated for
2 hours, and subsequently 4 mg/ml of biotin labelled antibody
(DAb) was added and incubated for 1 hour. To this St-HRPO (1:
5000 dilution) was added and the plate was incubated for
30 minutes. The plate was washed 3–5 times with PBST after
each of steps described above. Finally, TMB was added and the
developed colour was read at 650 nm using the microplate reader.
The mean of three readings for each concentration was plotted
against the corresponding concentration using Microsoft Excel.
2.6.2 Optimization of the DAb concentration. Biotin
labelled CS-35 MAb was used as the detection antibody. A fixed
concentration of CAb (8 mg/ml) was used to coat a microtitre plate
and varied concentrations of DAb ranging from 0 to 16 mg/ml (0,
1, 2, 4…16) were used. The assay protocol and the concentration
of the other parameters were same as described in section 2.6.1
and the data were similarly analyzed.
2.6.3 Optimization of the conjugate St-HRPO dilu-
tion. Serial two-fold dilutions of the conjugate St-HRPO (in
PBS with 1% BSA) ranging from 1:4,000 to 1:48,000 were used
i nt h ea s s a y .T h ep r e v i o u s l yo p t imised concentrations of the
other components such as CAb (8 mg/ml), DAb (2 mg/ml) and
BSA-Hex antigen (5 ng/ml) were kept constant. The assay was
performed as described in section 2.6.1 and the data was
similarly analyzed.
2.7 Optimization of BSA-Hex antigen detection sensitivity
The sensitivity of the assay was determined by measuring the
lowest amount of the antigen that can be detected by the assay.
Different concentrations of the BSA-Hex antigen ranging from
1 5 n g / m lt o0( 1 5 ,7 . 5 … … 0 )w e r eu s e dt o g e t h e rw i t ha b o v e
optimised concentration for CAb, DAb and conjugate St-HRPO.
The assay was performed in triplicate and repeated twice. All the
assaysreportedupuntilnowwasperformedinmicrotitreplate.Inthe
subsequent sections we reported the assays using the immunoswab.
2.8 Immunoswab assay
Both the MAb- and the bsMAb-based assays (format 1 and 2,
respectively, Figure 1) were carried out in the immunoswab
format. The swabs were coated with purified CS-35 (50 mLo f
25 mg/ml in PBS) at RT for 30 min, dried for 5 minutes and fixed
with 50 mL of 95% ethanol. The swabs were then blocked with 5%
DBSA in PBS at RT for 45 minutes and were washed five times
using PBST with one minute incubation in each washing step.
Washes were performed by a simple fill and aspiration method in a
microfuge tube. The washed swabs were incubated for 30 min
with different concentrations of BSA-Hex antigen in PBS
containing 1% DBSA. Subsequently the swabs were washed and
incubated for 30 minutes with either bsMAb (50 mLo f2 5mg/ml
in PBS containing 1% DBSA) in the bsMAb-based assay or with
biotin labelled CS-35 (50 mLo f4 mg/ml PBS containing 1%
DBSA) in the MAb-based assay. In the bsMAb-based assay, swabs
were washed five times as mentioned above and finally 100 mLo f
TMB was added for colour development. On the other hand, in
the MAb-based assay, the swabs were incubated with St-HRPO
(1:10000 dilution in PBS containing 1% DBSA) for 30 min and
were washed before TMB was added. The endpoint in both
formats was detected visually and compared with the blank swab
that was treated as described above except that it was incubated in
PBS without any antigen. Following colour development the swabs
were scanned using an Epson scanner.
2.9 Spiking of antigen in different matrices
Three different solute matrices, namely normal saline, rabbit
serum and bovine urine were used to spike the BSA-Hex antigen
and then the immunoswab assay was performed to check the limit
of detection in each matrix. The assay was performed as per above
protocol (section 2.8) in the bsMAb format. The concentration
range for the antigen was chosen in the 0–5 ng/ml range. Two
swabs were tested in each concentration.
2.10 Determination of the limit of detection of whole
LAM
The sensitivity of the assay (in bsMAb format) to detect whole
LAM isolated from a virulent strain of M. tuberculosis, H37Rv, was
determined. Different concentrations of the whole LAM antigen
were spiked in rabbit serum and the immunoswab assay was
performed in duplicate to test the limit of detection.
2.11 Determination of assay specificity
2.11.1 Assay performed with related synthetic
carbohydrate antigens. The specificity of the immunoswab
assay was determined using two different sugars, sucrose and BSA-
conjugated to the human blood group A trisaccharide (a kind gift
from Professor David R. Bundle, Department of Chemistry,
University of Alberta, Canada), together with the TB specific
antigen (BSA-Hex). Previous studies have established that the
human blood group A trisaccharide does not bind to CS-35 [28].
The immunoswab assay was performed as described above. All
three antigens were spiked in saline at 5 mg/ml concentration and
the assay was performed in duplicate using a higher concentration
range to check for cross reactivity.
2.11.2 Assay performed with different bacterial and
fungal culture. The assay was also separately evaluated using
the E.coli and yeast whole cell culture. The protocol was same as
before but here the swabs were incubated in the bacterial and
fungal culture after coating and blocking.
2.11.3 Assay performed with different native bacterial
and fungal carbohydrate antigens. The cross reactivity of the
assay was also checked by using different native carbohydrate
antigens. To check for cross-reactive responses to related
mycobacterial LAMs, we used LAM from Mycobacterium smegmatis
and Mycobacterium leprae (both were obtained from the Biodefense
and Emerging Infections Research Resources Repository
Manassas, Virginia, USA). As a related fungal antigen, we used
crude cell wall extract from Candida albicans (a kind gift from
Professor David R. Bundle, Department of Chemistry, University
of Alberta, Canada). Due to limited availability of these native
antigens, we performed a dot blot assay to check the cross
reactivity of the bsMAb. Briefly, two dots were made on
nitrocellulose membrane for each of the antigens. The amount
of antigen per dot was 1 mg. The dots were allowed to blot on the
membrane for 5 min. Then the membrane was blocked with 5%
skim milk for 45 min. Next it was washed with PBST for 3 times
and 3 ml of bsMAb (4 mg/ml) was added and incubated for
45 min. The membrane was washed 5 times with PBST buffer and
the color was developed using TMB substrate. As positive control,
we used BSA-Hex.
2.12 Evaluation of the assay with the clinical samples
A simple processing procedure was developed to reduce any
antibody–antigen immune complexes present in the sera (see
Immunoassay for Detecting Tuberculosis
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simulated samples and the optimized condition was tested with
the actual samples.
2.12.1 Optimization of the processing conditions. CS-35
was spiked in the rabbit serum (RS) along with the native LAM.
This was done to simulate the clinical samples. The MAb was
spiked at three different concentrations – 20 mg/ml, 2 mg/ml and
0.2 mg/ml and LAM was used at a concentration of 0.5 ng/ml in
all cases. Thus simulated samples were kept at 4uC overnight to
facilitate binding between the LAM antigen (Ag) and antibody
(Ab). The samples were then treated with different conditions as
described in Table 1. After processing, the samples were tested for
the antigen level by the developed immunoassay.
2.12.2 Processing of the clinical samples. In the
evaluation of the clinical samples, each was diluted 1:8 and was
then treated with urea and heat as specified in Table 1. Each
sample was tested in duplicate.
Results
3.1. Purification and biotin labelling of CS-35 producing
MAb
Purified CS-35 protein was analysed for binding to the BSA-
Hex by Western blotting. BSA-Hex (81.4 kDa) and BSA
(66.3 kDa) were run on SDS-PAGE (Fig. 2A.) and transferred to
nitrocellulose membrane, which was then probed with purified
CS-35 MAb (2 mg/ml). The goat anti-mouse IgG HRPO was used
as secondary antibody. A distinct band was observed only towards
BSA-Hex with no reactivity towards unconjugated BSA, confirm-
ing the specificity of CS-35 MAb towards the hexasaccharide
moiety of the LAM antigen (Fig. 2B).
Purified CS-35 MAb was labelled with biotin and labelling was
confirmed by a dot blot assay that was performed on a
nitrocellulose membrane. Both labelled and unlabelled MAb were
placed as dots on the membrane, unbound binding sites were
blocked and St-HRPO was added followed by TMB. A blue
colour, which is representative of a positive result, developed only
in the biotin labelled MAb dots confirming CS-35 MAb
biotinylation (data not shown).
3.2 Quadroma development
The dual labelled fused cells were sorted by FACS and the
fusion efficiency was found to be 0.9%. The positive cells were
screened by bridge ELISA and were repeatedly cloned by the
limiting dilution method. Cloning efficiency (n) was calculated at
each stage by using the following formula:
n~ no: of wells positive in ELISA=total no: of wells screened ðÞ
|100:
A gradual increase in both activity and cloning efficiency was
observed with each subsequent cloning stage. At the end of the
process two different quadroma clones (having cloning efficiency
.87%) secreting bsMAb were isolated.
Table 1. Different processing conditions for simulated serum samples.
Conditions Reagents used Temperature & time
1. No treatment Water=50 ml RT for 10 min
2. Glycine+Tris Glycine (0.1 M, pH 2.3)=40 ml
Tris (1 M, pH 9.0)=10 ml
RT for 10 min, First glycine was added and incubated for 5 min
before the solution was neutralised with Tris
3. Urea+heat Urea (8 M)=50 ml9 3 uC for 5 min followed by immediate cooling to 4uC.
4. SDS+heat SDS (10%)=20 ml
Water=30 ml
93uC for 5 min followed by immediate cooling to 4uC.
5. SDS+b-ME+heat SDS (10%)=20 ml
Water=28 ml
b-ME=2 ml
93uC for 5 min followed by immediate cooling to 4uC.
The abbreviations used, RT=Room temp, SDS=Sodium dodecyl sulphate, b-ME=b-mercaptoethanol.
doi:10.1371/journal.pone.0032340.t001
Figure 2. SDS-PAGE and Western blot of BSA-Hex and
unconjugated BSA. A: Coomassie stained SDS-PAGE gel showing
BSA-Hex, which contains 15.2 sugar residues per carrier, and
unconjugated BSA, running at 81.4 kDa and 66.3 kDa, respectively.
Lane M, standard molecular marker; lane 1, BSA-Hex; lane 2, BSA. B:
Probe of BSA-Hex and BSA after transfer to nitrocellulose with MAb CS-
35 in a Western blot showing reactivity only with BSA-Hex.
doi:10.1371/journal.pone.0032340.g002
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As mentioned before that the two-stage purification of bsMAb
was performed by as per published protocol [26]. The purified
fraction from the first step contained a mixture of three antibodies,
two parent MAbs (CS-35 and YP4) and bsMAb, all of them being
the IgG isotype. A second step of purification was performed using
m-amino phenyl boronic acid (m-APBA) agarose to get remove the
CS-35 MAb because its presence could affect the sensitivity of the
assay. The bsMAb, obtained from m-APBA column, was attached
to the reporter molecule HRPO via the HRPO-binding paratope.
After two stages of purification an increased bsMAb activity was
observed in the ELISA activity assay. The extent of purification
was confirmed by SDS-PAGE; three distinct bands were observed:
heavy chain (,50 kDa) and light chain (,25 kDa) of IgG
antibody, and HRPO (,44 kDa) (data not shown).
3.4 Optimization of assay parameters
After obtaining the purified CS-35 MAb, biotinylated CS-35
MAb, and bsMAb, different parameters of the assay were
optimized by sandwich ELISA (Fig. 1). Three different sets of
assays with different concentrations of capture antibody (CAb),
detection antobody (DAb) and St-HRPO were performed in
triplicate and repeated twice. In each set, only one parameter was
changed while the others were kept constant. The average of three
absorbance values was plotted against the respective concentration
using Microsoft Excel. In general, for each parameter of the assay,
there was an initial steady increase in absorbance value with
increasing concentration followed by a slow increase which
ultimately merged towards saturation becoming almost parallel
to the concentration axis. The point of transition between steady
increase and slow increase was chosen as the optimal condition for
the respective parameter. Only one set of the results for the
optimization of assay parameters was shown in Figure 3. The
optimal concentration was found to be 8.0 mg/ml for CAb
(Fig. 3A.), 4.0 mg/ml for DAb (Fig. 3B.) and 1:8000 dilution for St-
HRPO (Fig. 3C.).
3.5 Antigen detection limit
The assay was evaluated to determine the lowest amount of
BSA-Hex antigen that could be detected by the assay. The assay
was performed using optimized conditions with different concen-
trations of BSA-Hex starting from 15 ng/ml. After calculating the
statistical significance using Student t-test, 234 pg/ml was found to
be the limit of detection in a microtitre plate where p,0.05.
3.6 Comparison between biotinylated CS-35 and bsMAb-
based immunoswab format
The immunoassays were evaluated in both monoclonal- and
bispecific-based formats (Figure 1). The MAb-based assay (biotin–
CS-35) showed reduced sensitivity (5 ng/ml) than bsMAb format
(0.005 ng/ml) (data not shown). The high background with the
MAb-based approach can be explained by the following facts.
First, the chemical conjugation of the MAb is a random process
where the combination ratio between the MAb and the
conjugating chemical (biotin) is varied. In contrast, the bsMAb
has two different paratopes, one of which recognises the antigen of
interest, LAM and the other paratope binds to a reporter molecule
such as HRPO. Therefore, the ratio between the bsMAb and the
enzyme is always 1:1, which helps to provide a clear background.
Second, due to the random nature of this chemical conjugation,
the site of conjugation is also not fixed and as a result it may block
the antigen-binding site on the MAb, which leads to reduced
sensitivity. The higher sensitivity of bsMAb format prompted us to
use this format for the rest of the study.
3.7 Antigen detection limit in different matrices using
swab
Three different solution matrices, normal saline, rabbit serum
and bovine urine, were chosen to determine the limit of detection
of the antigen in each. This was done because during TB disease
the LAM antigen is present in blood and urine. Two swabs were
tested in each matrices. The limit of detection of BSA-Hex spiked
in saline was found to be 0.005 ng/ml in bsMAb-based assay,
while it was lower in serum and urine, 0.5 ng/ml and 5 ng/ml,
respectively (Fig. 4A).
3.8 Sensitivity of the assay using whole LAM
After the preliminary design of the assay using the chemically
synthesised antigen, the immunoswab assay was evaluated for its
sensitivity towards whole LAM antigen isolated from a virulent
strain of M. tuberculosis H37Rv strain. The whole LAM antigen was
spiked in rabbit serum and the immunoswab assay was performed
in the bsMAb format. The limit of detection of the assay was found
to be 0.5 ng/ml (Fig. 4B.). The native LAM was tested only in
serum as the designed assay was found to be more sensitive in
serum than in urine.
3.9 Specificity of the assay
The complete specificity analysis was summarised in Table 2.
The designed assay showed no cross reactivity with the structurally
unrelated synthetic antigens (sucrose and BSA-conjugated to the
human blood group A trisaccharide). In addition, no colour was
detected in the assay performed with the E.coli and yeast culture.
Similar results were obtained in the dot blot assay, against the
native candida antigen. However, the antibody showed reactivity
with native LAM from both Mycobacterium smegmatis and Mycobac-
terium leprae, which would be expected because CS-35 recognizes
an epitope common to all LAMs.
3.10 Evaluation of the assay with clinical samples
In initial studies with the clinical samples, the signal in the assay
was reduced compared to the spiked samples. Based on several
earlier published works, we hypothesized that this was due to the
presence of immune complexes (IC) between LAM and cognate
antibodies in the sera [42–44]. We therefore explored dissociating
the IC either with acidification or with reduction or denaturation.
As illustrated in Fig. 5A, in a series of test samples, among all of the
conditions explored, adding urea and then heating worked best to
dissociate the IC and gave the highest sensitivity. The same trend
was observed in all the three Ab concentrations tested.
When applied to the clinical samples, the same effect was
observed (Fig. 5B). Pre-treatment of the sample with urea
enhanced the specific antigen detection signal in the positive
samples (those with numerical sample number). At the same time,
it reduced the background for the negative samples (those with
alpha-numerical sample number).
We chose to work with the stored serum samples collected from
TB patients as the designed assay showed more sensitivity in the
serum matrix. Each sample was tested in duplicates. Based on the
mean absorbance value of the negative samples the cut-off point
was chosen as mean+2 SD (standard deviation). All the negative
samples were found to be negative as they all were below the cut-
off point (green bars in Fig. 6). This established 100% specificity of
the assay. Of the cavitary TB samples 9 out of 14 positive samples
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in Fig. 6), leading to a sensitivity of 64%.
Discussion
In this study, the LAM antigen of M. tuberculosis was the target
for the development of an immunoswab assay to diagnose TB.
M. tuberculosis produces copious quantities of LAM which has been
shown to be secreted in vitro and in vivo LAM [45], and therefore
detection of LAM can be efficiently done during the early stage of
the disease. LAM has been shown to be present in not only sputum
but also in blood, urine, pleural fluid and cerebrospinal fluid of M.
tuberculosis infected patients [19–24]. The occurrence of LAM in
body fluids other than sputum especially facilitates the detection of
extra-pulmonary TB. Also, compared to sputum collection, it is
relatively easy to collect blood or urine samples. The immunoswab
assay reported here is capable of detecting LAM spiked in both
serum and urine, indicating that the assay will be useful in
detecting pulmonary, extra-pulmonary and disseminated TB.
In a study by Arias-Bouda et. al involving detection of LAM in
sputum samples, a polyclonal antibody was employed as the
detection antibody and it was found that the sensitivity and
specificity of the assay were 94% and 100%, respectively [20]. In
our study, an anti-LAM MAb was used to develop a bsMAb,
which was then employed as the detection antibody in the assay.
In comparison with polyclonal antibodies, an advantage of
bsMAbs is that they can be produced with less batch-to-batch
reproducibility [46–48], which is beneficial to the long-term
robustness of an assay. In addition, as mentioned earlier (section
3.6), both MAb- and PAb- based assays require a secondary
antibody–enzyme conjugate, which is typically produced by
chemical conjugation, a process that is also not uniformly
reproducible [49]. Moreover, because the bsMAb is already
tagged with HRPO, extra steps involving secondary antibody
addition and subsequent washes are avoided. This contributes to
an overall reduction of time required for the immunoswab assay.
Arias-Bouda et al. also reported a correlation between the amount
of LAM and the corresponding bacterial load [20]. According to
that correlation, our assay should be able to detect 5610
3 bacilli/
ml as the detection limit for native LAM using the bsMAb was
found to be 0.5 ng/ml in serum.
Figure 3. Optimization of different assay parameters. A: Optimisation of the capture antibody (CAb), where the concentration 8 mg/ml was
found to be optimum. B: The optimisation of detection antibody (DAb), where the concentration 4 mg/ml was found to be optimum. C: The
optimisation of conjugate (st-HRPO), where the dilution 1:8,000 was found to be optimum.
doi:10.1371/journal.pone.0032340.g003
Figure 4. Immunoswab in different matrices. A: The immunoswab
performed after spiking the BSA-Hex antigen in serum and urine and
the limit of detection (LOD) was found to be 0.5 and 5.0 ng/ml in
respective matrices (encircled in red). B: The immunoswab performed
after spiking the bacterial LAM isolated from M. tuberculosis H37Rv, in
serum and the LOD was found to be 0.5 ng/ml.
doi:10.1371/journal.pone.0032340.g004
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commercially available although the assay has restricted sensitivity
[50–52]. Recently, a lateral flow POC assay (Alere Determine TB)
has been released and shown to be effective, especially when
combined with smear-sputum microscopy [53]. Both assays
usually employ urine samples and performed well in patients with
advanced immune suppression, which are particularly difficult to
diagnose [52–53]. We anticipate that should the immunoswab
assay format described here prove inadequate, the bsMAb
reported here may be of use in the development of lateral flow
assays analogous to Alere Determine TB.
The specificity was checked with different synthetic carbohydrate
antigens, as well as native carbohydrate antigens. The assay was
found to be specific towards the target antigen. However, cross
reactivity was detected with non-tuberculous mycobacterial LAMs.
Out of all the serum processing conditions tested, the urea and
heat treatment was best to dissociate putative Ab–Ag immune
complexes. This approach was superior to the use of either SDS or
b-mercaptoethanol, which are, respectively, potent protein
denaturing or reducing agents. The result can be explained by
the presence of excess processing reagent during the immunoassay.
For example, the presence of SDS in the processed sample could
reduce signal by inhibiting the Ab–Ag attachment in the
subsequent immunoassay. In contrast, the presence of excess urea
was not expected to be problematic as it mainly denatures proteins
at temperatures above 60uC [54]. Therefore, because we
conducted the immunoassay at RT the presence of urea little
interference is likely. With regard to glycine and tris treatment of
samples, a report in literature that showed that this treatment can
dissociate Ab–Ag complexes but that one hour of incubation is
Table 2. Specificity study of the assay.
Category Antigen Results
Immunoswab Dot blot
Synthetic carbohydrate Sucrose 2ve NP
BSA-conjugated to the human blood group A trisaccharide 2ve NP
BSA-Hex (specific antigen) +ve +ve
Bacterial culture E.coli (strain HB2151) 2ve NP
Fungal culture Yeast (strain A364A) 2ve NP
Native carbohydrate antigens LAM from Mycobacterium smegmatis NP +ve
LAM from Mycobacterium leprae. NP +ve
Crude cell wall extract from Candida albicans NP 2ve
The specificity was evaluated either of the two formats – immunoswab or dot blot. +ve=blue colour developed; 2ve=no blue colour. NP means not performed in the
corresponding format. The +ve outcomes are in bold.
doi:10.1371/journal.pone.0032340.t002
Figure 5. The effect of chemical treatment on the antigen detection level in the simulated and clinical samples. A: The effect of
different chemical treatments (as mentioned along x-axis) on antigen detection level (in simulated samples). The three different antibody
concentrations are mentioned at the top right hand side. Each condition (under each antibody concentration) was tested in triplicates. B: The antigen
level detected with the clinical samples. The clear bar shows the result without (w/o) any pre-treatment while the pre-treated samples are shown via
the dark bar. The first four samples were negative and rest were positive clinical samples. Each sample was tested in duplicate.
doi:10.1371/journal.pone.0032340.g005
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facilitating high throughput sample testing, we processed the
samples only for 10 min, which was probably insufficient to fully
dissociate immune complexes with these reagents.
The specificity (100%) of the assay was further established in the
analysis with the clinical samples. The sensitivity (64%) of the assay
with the clinical samples was not high. A possible explanation is
that the 14 TB serum samples selected from a group of 30 cavitary
TB individuals that showed the highest anti-LAM titer [34], not
the presence of the antigen, which is the basis of the assay
described here.
To design an assay having visually detectable end point, we
transformed the assay from an ELISA plate to a swab format. The
transformation reduced the sensitivity. The corresponding antigen
detection limit in buffer was 0.234 ng/ml in an ELISA plate
(section 3.5) and 5 ng/ml in swab (section 3.6) when performed in
MAb based format. However, as noted earlier (section 3.6), the
MAb based format was found to be less sensitive in the swab
format than the bsMAb format. It should be noted that a
limitation of the assay, or any assay relying on visual end point
detection, is inter observer variability, which, in turn, influences
the sensitivity. To minimize the inter observer variability, the
result of the assay should always be compared with a suitable
negative control; however, this issue can never be completely
overcome.
The assay reported in this study is simple, easy to perform and
results can be obtained within 2–3 hours of sample collection.
Although the assay demands a couple of washing (fill and aspirate)
and incubation steps, we believe that can be easily done by the
personnel with minimal technical training. Furthermore, the cost
of the reagents required to perform the assay is less than 1.00 CAD
per swab (cost analysis not shown), making it inexpensive. Another
advantage of this assay is that the assay endpoint can be read
visually without using any sophisticated instrumentation. This type
of easy, low cost and fast access to results can encourage people to
start the diagnostic process [56]. It is believed that a rapid and less
sophisticated detection test, even one having poor sensitivity like
the SSM, could avert 15% of the annual deaths due to TB [56].
We note that the assay described in this study has all the
characteristics of an ideal diagnostic test – affordable, sensitive,
specific, user-friendly, rapid and robust, equipment-free and
delivered to those in need (ASSURED) [57].
One of the potential limitations of the assay evaluation was that
we used only 21 clinical samples and they were kept frozen for a
significant time. This might have caused the wide confidence
interval along with the reduced sensitivity. The use of a larger
number of samples would have allowed us to evaluate the assay
better. In future, we want to extend the evaluation of our assay
with a greater number of freshly collected serum samples from TB
and HIV co-infected patients
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